TheEdgeResearch
Home / Stocks / NYXH

Nyxoah S.A. (NYXH)

NASDAQ Healthcare Medical - Specialties
$0.81 ▼ -6.25%
Market Cap
$82.0M
Sector
Healthcare
Industry
Medical - Specialties
Beta
1.02
52-Wk Range
0.8-5.39
CEO
Liam J. Kelly
Country
BE
Currency
USD

Nyxoah S.A. operates in the Medical - Specialties industry of the Healthcare sector, headquartered in Mont-Saint-Guibert, WA, BE. The stock last traded at $0.81, down 6.25% on the session, giving a market capitalisation of $82.0M. On trailing twelve-month figures it carries a trailing P/E of -0.43, a net margin of -310.6%. Its beta of 1.02 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.43
Price / Sales
2.50
Price / Book
1.09
EV / EBITDA
-1.66
Gross margin
54.3%
Operating margin
-282.9%
Net margin
-310.6%
Return on equity
—
Debt / equity
0.79
Current ratio
2.19
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ
Employees
154
IPO date
2021-04-28
Headquarters
Mont-Saint-Guibert, WA, BE
About Nyxoah S.A.

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Comparable companies

Nyxoah S.A. is most often compared with the following Healthcare names:

CATXGNFTIVVDKRMDOABIOSURPRESTIMTARAUTMD
More research on NYXH
NYXH technical analysis NYXH TheEdge Score Compare against peers
Open full interactive analysis & DCF →